RBC Capital notes that it was announced that the Court of Appeals denied Regeneron’s (REGN) motion for an emergency injunction and the temporary stay has been lifted. The Court of Appeals, however, did grant agreed-upon expedited briefing and oral argument in this appeal, with an oral hearing scheduled to be held in January 2025. Though Amgen (AMGN) is now more able to launch their biosimilar Eylea at risk, the firm sees “multiple reasons why downside from here is not warranted,” arguing that the worst case is “likely already more than baked in.” The firm, which adds that it would buy on weakness, has an Outperform rating and $1,260 price target on Regeneron shares.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron announces three-year data for EYLEA HD Injection 8 mg study
- Regeneron price target lowered to $1,137 from $1,200 at Truist
- RBC Capital remains bullish on Regeneron, continues to see buying opportunity
- Disney upgraded, JPMorgan downgraded: Wall Street’s top analyst calls
- Regeneron downgraded to Hold from Buy at Erste Group